PT  - JOURNAL ARTICLE
AU  - Sublette, Marcus G.
AU  - Cross, Tzu-Wen L.
AU  - Korcarz, Claudia E.
AU  - Hansen, Kristin M.
AU  - Murga-Garrido, Sofia M.
AU  - Hazen, Stanley L.
AU  - Wang, Zeneng
AU  - Oguss, Madeline K.
AU  - Rey, Federico E.
AU  - Stein, James H.
TI  - Effects of Smoking and Smoking Cessation on the Intestinal Microbiota
AID  - 10.1101/2020.07.11.20151480
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.11.20151480
4099  - http://medrxiv.org/content/early/2020/07/14/2020.07.11.20151480.short
4100  - http://medrxiv.org/content/early/2020/07/14/2020.07.11.20151480.full
AB  - Introduction We evaluated associations of smoking heaviness markers and the effects of smoking cessation on the intestinal microbiota and cardiovascular disease risk factors in current smokers undertaking a quit attempt.Methods and Results Participants were current smokers enrolled in a randomized clinical trial of smoking cessation therapies with visits, risk factor measurements, and fecal collections at baseline, 2, and 12 weeks after starting a quit attempt. Genomic DNA was extracted from fecal samples followed by 16S rRNA gene sequencing and analysis using the QIIME2 software workflow. Relative abundances of bacterial taxa and alpha- and beta-diversity measures were compared.Longitudinal changes in bacterial taxa abundances were compared using analysis of covariance (ANCOVA). The 36 smokers were (mean [standard deviation]) 51.5 (11.1) years old (42% male) and smoked 15.1 (6.4) cigarettes per day for 22.7 (11.9) pack-years. Their exhaled carbon monoxide (CO) levels were 17.6 (9.3) ppm. At baseline, relative abundances of the phylum Actinobacteria were correlated inversely with pack-years (rho=-0.44, p=0.008) and Cyanobacteria were correlated positively with CO levels (rho=0.39, p=0.021). After 12 weeks, abundances of the phylaBacteroidetes increased (pANCOVA=0.048) and Firmicutes decreased (pANCOVA=0.036) among abstainers compared to continuing smokers. Increases in alpha-diversity were associated with lower heart rates (rho=-0.59, p=0.037), systolic blood pressures (rho=-0.58, p=0.043), and C-reactive protein levels (rho=-0.60, p=0.034).Conclusions Smoking cessation leads to minor changes in the intestinal microbiota. It is unclear if the proven health benefits of smoking cessation lead to salutary changes in the intestinal microbiota and if such changes affect cardiovascular disease risk.Implications In the largest prospective study of current smokers making a quit attempt to date, we showed that smoking cessation has minor effects on the composition of the gut microbiome. In successful abstainers, relative abundances of the phyla Bacteroidetes increased and Firmicutes decreased, a pattern of uncertain clinical significance. We did not observe significant changes in alpha- or beta-diversity with smoking cessation. It is unclear if the proven health benefits of smoking cessation lead to salutary changes in the intestinal microbiota and if such changes affect cardiovascular disease risk.Competing Interest StatementMarcus G. Sublette, MD: None Tzu-Wen L. Cross, PhD, RD: None Claudia E. Korcarz, DVM: None Kristin M. Hansen, BS: None Sofia M. Murga-Garrido, MD: None Stanley L. Hazen, MD, PhD: Co-inventor on pending and issued patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics; royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland Heart Lab and Procter & Gamble; paid consultant for Procter & Gamble; received research funds from Procter & Gamble, Pfizer Inc., and Roche Diagnostics Zeneng Wang, PhD: Co-inventor on pending and issued patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics; royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland Heart Lab and Procter & Gamble Madeline K. Oguss, MS: None Federico E. Rey, PhD: None James H. Stein, MD, FAHA: None Clinical TrialNCT03176784Funding StatementThe QUITS study was funded by grant 2 R01 HL109031 from the National, Heart, Lung, and Blood Institute. T-W.L.C was supported by a National Institutes of Health Ruth L. Kirschstein National Research Service Award T32 HL 007936 from the National Heart Lung and Blood Institute to the University of Wisconsin-Madison Cardiovascular Research Center. SLH and ZW were supported by grants P01HL147823 and R01HL103866 from the NIH and Office of Dietary supplements. SLH and FR were also partially supported by an award from the Leducq Foundation. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Wisconsin Health Sciences Institutional Review Board, Madison, WIAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request